BulletinFeb 06, 2017

2017-0204 - Suspension - Abattis Bioceuticals Corp. (ATT)

February 6, 2017

Abattis Bioceuticals Corp. is in default of CSE requirements. Effective immediately, Abattis Bioceuticals will be suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules.  A cease trade order has been issued by the British Columbia Securities Commission and the Ontario Securities Commission.

Date: Effective immediately, February 6, 2017

Symbol: ATT

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: [email protected]

Follow us for the latest news from the CSE